Dr. Funchain specializes in medical oncology of melanoma, high risk skin cancers, and cancer genetics. She offers additional expertise in other cutaneous malignancies, Merkel cell carcinoma, skin cancer genomics, and immunotoxicology in the Division of Oncology at Stanford Cancer Center. She previously served as Director of the Melanoma Oncology Program, co-Director of the Comprehensive Melanoma Program, as well as Director of the Genomics Program at the Taussig Cancer Institute of the Cleveland Clinic. 

At Stanford, Dr. Funchain specializes in cutaneous malignancies and cancer. She codirects the Skin Cancer Genomics Program as well as the Immune Related Toxicity Working Group at Stanford. Nationally, Dr. Funchain co-chaired the inaugural American Society of Clinical Oncology (ASCO) Guidelines Panel on Systemic Therapy in Melanoma and serves on the ASCO Guidelines Panel on Immune Related Adverse Events (irAEs). She developed and led the first irAE tumor board established in the US as well as the Management of Checkpoint Inhibitor Toxicity, the first medical conference focused on the advancement of irAE management.

Additionally, Dr. Funchain conducts translational science research focusing on the genetics and genomics, both germline and somatic, of cancer. Her primary research interests are in the genetics and genomics of melanoma, the practical translation of genomic data into clinical precision oncology, and predictors of clinical outcomes and adverse events related to immunotherapy. 

She received a Bachelor of Arts in Bioethics from Pomona College and her medical degree from the Ohio State College of Medicine. She completed internal medicine training at Harbor-UCLA Medical Center and a hematology-oncology fellowship at the Cleveland Clinic, after which she completed the Ambrose Monell Fellowship in Cancer Genomics at the Genomic Medicine Institute of the Cleveland Clinic. Dr. Funchain is board certified in medical oncology.